Israeli pharmaceutical firm Teva Pharmaceutical Industries says Dr Michael Hayden will join the company as president of Global Research and Development and Chief Scientific Officer. Hayden will lead all r&d for Teva, combining two teams focused on the development of branded and generic medicines.
Hayden is currently Killam Professor of Medical Genetics at the University of British Columbia, and Canada Research Chair in Human Genetics and Molecular Medicine. He is also founder and director/senior scientist of the Centre for Molecular Medicine and Therapeutics at the University of British Columbia. He is an expert in genetics and personalised medicine, as well as in Huntington’s disease.
Hayden has founded three biotechnology companies: NeuroVir; Aspreva Pharmaceuticals; and Xenon Genetics.
